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Some chemokines specifically attract T helper 1 (Th1) cells, whereas others attract T helper 2 (Th2) cells. In this
study, we investigated the capacity of Langerhans cells (LC) to produce Th1- and Th2-type chemokines in com-
parison with that of splenic CD11cþ dendritic cells (DC). We prepared highly puriﬁed (495%) LC from BALB/c
mouse skin using the panning method. With regard to Th1-type chemokines, exogenous stimulus, such as in-
terferon-c (IFN-c), lipopolysaccharide, or polyinosinic–polycytidylic acid, was mandatory for the production of
substantial amounts of CXCL10, CXCL9, and CXCL11 both in LC and splenic DC. LC, as a whole, exhibited low
ability to produce Th1-type chemokines in comparison with splenic DC. As for Th2-type chemokines, LC, but not
splenic DC, produced high levels of CCL22 and CCL17 constitutively during culture even without exogenous
stimuli. The production of Th2-type chemokines was regulated in a complicated manner. In particular, interleukin-4
upregulated, and IFN-c downregulated both CCL22 and CCL17 production by LC. Of note, LC produced much
more amounts of Th2-type chemokines than splenic DC under any conditions tested. Finally, Th1- and Th2-type
chemokines produced by LC were shown to be functional using chemokine receptor-transfected-2B4 T cells. The
high production of CC chemokine receptor 4 ligands by LC in the absence of IFN-c may be an important character
discriminating LC from other DC.
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Chemokines are chemotactic cytokines that play an impor-
tant role in regulating leukocyte migration (Baggiolini, 1998;
Zlotnik and Yoshie, 2000). T helper 1 (Th1) and T helper 2
(Th2) cells express different types of chemokine receptors
and respond to distinct types of chemokines. CXC chemo-
kine receptor 3 (CXCR3) is predominantly expressed on Th1
cells (Bonecchi et al, 1998; Sallusto et al, 1998; Zlotnik and
Yoshie, 2000). Interferon (IFN-g)-inducible protein-10 (IP-
10)/CXCL10 (Zlotnik and Yoshie, 2000), monokine induced
by IFN-g(Mig)/CXCL9 (Zlotnik and Yoshie, 2000), and IFN-
inducible T cell a chemoattractant (I-TAC)/CXCL11 (Zlotnik
and Yoshie, 2000) all bind to CXCR3, and thus promote the
migration of Th1 cells. On the other hand, CC chemokine
receptor 4 (CCR4) is predominantly expressed on Th2 cells
(Sallusto et al, 1998; Imai et al, 1999; Zlotnik and Yoshie,
2000), CD4þCD25þ T cells with regulatory activity (Iellem
et al, 2001; Sebastiani et al, 2001), and also on skin homing
memory T cells positive for cutaneous lymphocyte antigen
(CLA) (Campbell et al, 1999). Thymus and activation-regu-
lated chemokine (TARC)/CCL17 (Zlotnik and Yoshie, 2000)
as well as macrophage-derived chemokine (MDC)/CCL22
(Zlotnik and Yoshie, 2000) promote the migration of these
cells via CCR4.
Dendritic cells (DC) are professional antigen-presenting
cells with a unique ability to stimulate naı¨ve T cells and in-
itiate primary immune responses (Liu, 2001). Distinct DC
subpopulations exhibit distinct functions leading to different
immune regulations (Banchereau et al, 2000; Liu, 2001), and
their heterogeneity reflects the organs they reside in (Reis e
Sousa et al, 1999). Langerhans cells (LC) are a specific
subtype of DC localized in the epidermis (Banchereau and
Steinman, 1998). LC differ from other DC in possessing
Birbeck granules, lacking functional mannose receptors,
expressing E-cadherin, and being dependent on transform-
ing growth factor-b (TGF-b) for their differentiation (Ban-
chereau and Steinman, 1998; Banchereau et al, 2000; Wu
et al, 2001). As for functional characteristics of LC in com-
parison with those of splenic DC, we have reported the
unique modality in the regulation of interleukin-12 (IL-12)
production (Tada et al, 2000, 2001) and inability of IFN-g
production (Tada et al, 2003) in LC. Furthermore, we have
found substantial differences in responsiveness to micro-
organisms through Toll-like receptors between LC and
splenic DC (Fujita et al, 2004b; Mitsui et al, 2004; Tada
et al, 2004).
Abbreviations: Ab, antibody; DC, dendritic cells; LC, Langerhans
cells; LN, lymph nodes; LPS, lipopolysaccharide; GM-CSF, gran-
ulocyte macrophage colony-stimulating factor; IFN, interferon; IL,
interleukin; mAb, monoclonal antibody; Poly(IC),polyinosinic–poly-
cytidylic acid; SAC, Staphylococcus aureus Cowen 1; Th1, T helper
1; Th2, T helper 2; TNF-a, tumor necrosis factor-a; TGF-b, trans-
forming growth factor-b
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Not only are DC attracted by chemokines but DC are also
an abundant and strategic source of various chemokines
(Sallusto et al, 1999). In addition, a recent report disclosed
that the property of chemokine production is diverse among
DC subsets (Penna et al, 2002a, b). We have recently re-
ported the expression and regulation of inflammatory
chemokines, such as CCL3, CCL4, and CCL5, in mouse
LC (Fujita et al, 2004a). Apart from this study, however,
chemokine production by resident LC has not been well
described. In particular, it is unknown whether LC are ca-
pable of producing the Th1-type chemokines, CXCL10,
CXCL9, and CXCL11.
In this study, in order to further define functional prop-
erties of LC to shape immune responses, we focused on the
expression and regulation of Th1- and Th2-type chemo-
kines in mouse LC. For this purpose, we prepared highly
purified LC population (495%) from mouse skin, which was
phenotypically immature and acquired mature phenotypes
during culture in vitro (Salgado et al, 1999a, b; Tada et al,
2000). Furthermore, we used splenic CD11cþ DC for com-
parison with LC, and illustrated distinct characteristics of LC
in chemokine production.
Results
Messenger RNA for Th1-type chemokines in LC and
splenic DC CXCL10, CXCL9, and CXCL11 are Th1-type
chemokines that are structurally related and share the com-
mon receptor CXCR3 (Olson and Ley, 2002). To investigate
whether LC and splenic DC express their mRNA, semi-
quantitative RT-PCR analysis was performed. The mRNA of
none of these Th1-type chemokines was detected in fresh
LC (Fig 1). After 48 h culture, LC came to express CXCL10
and CXCL11, but not CXCL9, mRNA. Expression of CXCL9
mRNA was strongly induced by IFN-g. These results indi-
cate that mRNA expression of CXCL9 is regulated dif-
ferently from that of CXCL10 and CXCL11 during the mat-
uration of LC. In the case of splenic DC, the expression of
mRNA for all three chemokines was negligible in fresh and
unstimulated cultured cells. mRNA for CXCL10, CXCL9,
and CXCL11 was, however, induced by IFN-g.
Time-course measurement of the production of Th1-
type chemokines by LC and splenic DC To determine
whether Th1-type chemokines were produced at protein
level by cultured LC and splenic DC and secreted into cul-
ture media, ELISA was carried out using media cultured for
0, 12, 24, 36, and 48 h. As shown in Fig 2, without IFN-g
treatment, LC and splenic DC produced small amounts of
Th1-type chemokines. In contrast, LC and splenic DC
produced substantial amounts of CXCL10, CXCL9, and
CXCL11 time dependently by stimulation with IFN-g (100 ng
per mL). Splenic DC have, on the whole, an ability to pro-
duce larger amounts of Th1-type chemokines than LC.
Biological activity of Th1-type chemokines produced
by LC and splenic DC To ascertain whether Th1-type
chemokines produced by LC and splenic DC were func-
tional, culture supernatants were tested for their capacity to
induce the migration of CXCR3-transfected 2B4 Tcells (Gao
et al, 2003). As demonstrated above, CXCR3 ligands are
produced at large amounts by stimulation with IFN-g both in
LC and splenic DC. Indeed, the supernatants of 48 h cul-
tured unstimulated LC and splenic DC induced only minimal
migration of these cells (data not shown). Therefore, we
used the supernatants of 48 h cultured IFN-g-treated LC
and splenic DC for the chemotaxis of CXCR3 transfectant.
As shown in Fig 3, the supernatant of LC exhibited consid-
erable chemotactic activity to CXCR3 transfectant. Neu-
tralizing anti-CXCL10 antibody (Ab) and anti-CXCL9 Ab
partially blocked the migration, respectively. When both
of the Abs were added simultaneously, the migration of
transfectant was almost completely inhibited. The supe-
rnatant of splenic DC induced more prominent migration of
the transfectant than that of LC. In the same way, this mi-
gration was partially blocked by anti-CXCL10 Ab or anti-
CXCL9 Ab, respectively, and almost completely blocked by
both of them. Isotype-matched control of neutralizing Ab
did not affect the migration of transfectant (data not shown).
These results indicate that at least CXCL10 and CXCL9
produced by LC and splenic DC actually possess chemo-
tactic activity, and the contribution of CXCL11 for the mi-
gration of the transfectant seems to be minimal both in LC
and splenic DC.
Messenger RNA for Th2-type chemokines in LC and
splenic DC CCL22 and CCL17 are Th2-type chemokines
that share the receptor CCR4. Therefore, we analyzed the
mRNA expression of CCL22 and CCL17 in LC and splenic
DC by semi-quantitative RT-PCR. As shown in Fig 4, CCL22
and CCL17 showed almost the same pattern of mRNA ex-
pression in fresh and cultured LC. The mRNA of both
chemokines was only faintly detected in fresh LC, and
strongly expressed after 48 h culture. The results obtained
Figure 1
RT-PCR analysis of CXCL10, CXCL9, and CXCL11 gene expression
in freshly isolated Langerhans cells (fLC), 48 h cultured LC (cLC),
interferon-c (IFN-c)-stimulated cLC (c-cLC), freshly isolated splenic
dendritic cells (fDC), 48 h cultured splenic DC (cDC), and IFN-c-
stimulated cDC (c-cDC). LC and splenic DC were purified and cul-
tured for 48 h in the absence or presence of 100 ng per mL of IFN-g.
Samples from fresh and cultured LC and splenic DC were collected
and mRNA expression was analyzed using specific primers for each
chemokine. CXCL10, CXCL9, and CXCL11 mRNA expression was
hardly detectable in fLC. In cLC, mRNA expression of CXCL10 and
CXCL11, but not CXCL9, was induced. CXCL9 mRNA was strongly
expressed only in g-cLC. In addition, mRNA for CXCL10 and CXCL11
was also strongly expressed in g-cLC. In splenic DC, mRNA for these T
helper 1(Th1)-type chemokines was almost undetectable both in fDC
and cDC. When stimulated with IFN-g, CXCL10, CXCL9, and CXCL11
mRNA expression was induced. Data are representative of three inde-
pendent experiments.
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for CCL17 were consistent with those reported previously
(Xiao et al, 2003a). In sharp contrast, fresh splenic DC did
not express mRNA for Th2-type chemokines. Of note,
mRNA for CCL22 and CCL17 was not induced in splenic DC
even after culture.
Time-course measurement of the production of Th2-
type chemokines by LC and splenic DC CCL22 and
CCL17 production by LC and splenic DC was determined
by ELISA using media cultured for 0, 12, 24, 36, and 48 h.
As shown in Fig 5, LC produced substantial levels of these
chemokines in a time-dependent manner even in the ab-
sence of exogenous stimulation. Conversely, splenic DC in
the same condition failed to produce Th2-type chemokines
at any time point up to 48 h. These results were in parallel
with mRNA expression analyzed by RT-PCR.
Biological activity of Th2-type chemokines produced by
LC and splenic DC To investigate whether Th2-type
chemokines produced by LC and splenic DC have chemo-
tactic activity to T cells, we carried out a chemotaxis assay
using CCR4-transfected 2B4 T cells (Gao et al, 2003). The
results shown in Fig 6 demonstrate that the supernatant of
48 h cultured unstimulated LC induced the migration of a
considerable number of CCR4 transfectant. This migration
was partially blocked by neutralizing anti-CCL17 Ab and
anti-CCL22 Ab, respectively. When both of the Ab were
Figure 2
Production of T helper 1-type chemokines during culture of Langerhans cells (LC) and splenic dendritic cells (DC). Purified LC and splenic
DC were cultured with or without interferon-g (IFN-g), and the concentration of CXCL10, CXCL9, and CXCL11 was measured at different time points
(0, 12, 24, 36, 48 h) in the supernatants by ELISA. Representative data of three independent experiments.
Figure 3
Chemotaxis of mCXCR3-transfected 2B4 T cells. Langerhans cells
(LC) and splenic dendritic cells (DC) were cultured for 48 h with 100 ng
per mL of interferon-g (IFN-g) and the supernatants were collected. The
culture supernatants were preincubated with or without neutralizing
anti-chemokine monoclonal antibody (mAb) indicated in the figure for
30 min, and assessed for chemotactic activity to CXCR3 transfectant.
RPMI 10 medium alone served as a negative control. RPMI 10 medium
containing recombinant chemokine served as a positive control. The
supernatants of IFN-g-stimulated LC and splenic DC exhibited chemo-
tactic activity to CXCR3 transfectant, which is mediated at least by
CXCL10 and CXCL9. Mean  (SD) (n¼3). Data are representative of
three independent experiments.
Figure4
RT-PCR analysis of CCL22 and CCL17 gene expression in freshly
isolated Langerhans cells (fLC), 48 h cultured LC (cLC), freshly
isolated splenic dendritic cells (fDC), and 48 h cultured splenic DC
(cDC). LC and splenic DC were purified and cultured for 48 h without
exogenous stimulation. mRNA of fresh and cultured LC and splenic DC
was extracted, and mRNA expression was analyzed using specific
primers for each chemokine. CCL22 and CCL17 mRNA was expressed
weakly in fLC, and strongly in cLC. In splenic DC, mRNA for CCL22 and
CCL17 was not detected both in fDC and cDC. Data are representative
of two independent experiments.
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added simultaneously, the migration of the transfectant
was inhibited almost completely. On the other hand, the
supernatant of 48 h cultured splenic DC exhibited mini-
mal chemotactic activity to CCR4 transfectant. These re-
sults confirm that CCL22 and CCL17 produced by LC are
functional.
Production of Th1-type chemokines and its regulation in
LC and splenic DC As mentioned above, IFN-g-stimulated
LC and splenic DC produced a substantial level of Th1-type
chemokines. To investigate the production of Th1-type
chemokines and their regulation in LC and splenic DC, we
cultured them with various stimuli. As shown in Fig 7a, in
addition to IFN-g, IL-12 (2 ng per mL), lipopolysaccharide
(LPS) (1 mg per mL), Staphylococcus aureus Cowen 1 (SAC)
(1:10000), and polyinosinic–polycytidylic acid (Poly(I:C)) (20
mg per mL) induced CXCL10 production in LC. In the case of
CXCL9 and CXCL11, of all the stimuli tested, only IFN-g
induced the production of these chemokines in LC (Fig
Figure 6
Chemotaxis of mCCR4-transfected 2B4 T cells. Langerhans cells
(LC) and splenic dendritic cells (DC) were cultured for 48 h without
stimulation and the supernatants were collected. The culture supe-
rnatants were preincubated with or without neutralizing anti-chemokine
monoclonal antibody (mAb) indicated in the figure for 30 min, and as-
sessed for chemotactic activity to CCR4 transfectant. RPMI 10 medium
alone served as a negative control. RPMI 10 medium containing re-
combinant chemokine served as a positive control. The supernatant of
LC, but not of splenic DC, exhibited CCL22- and CCL17-dependent
chemotactic activity to CCR4 transfectant. Mean  (SD) (n¼3). Data
are representative of three independent experiments.
Figure 5
Production of T helper 2-type chemokines during culture of La-
ngerhans cells (LC) and splenic dendritic cells (DC). Purified LC and
splenic DC were cultured without exogenous stimulation, and the con-
centration of CCL22 and CCL17 was measured at different time points
(0, 12, 24, 36, 48 h) in the supernatants by ELISA. Data are represent-
ative of three independent experiments.
Figure7
Regulation of T helper 1-type chemokines produced by La-
ngerhans cells (LC) and splenic dendritic cells (DC). LC (&) and
splenic DC (’) were purified and cultured (1.5  106 cells per mL per
200 mL in each well) for 48 h with or without various stimuli. The supe-
rnatants were collected and the concentration of CXCL10 (a), CXCL9
(b), and CXCL11 (c) was measured by ELISA. CXCL10 production by
LC was induced by interferon-g (IFN-g), interleukin (IL)-12, lipopoly-
saccharide (LPS), Staphylococcus aureus Cowen 1 (SAC), and poly-
inosinic–polycytidylic acid (Poly(I:C)). In the case of CXCL9 and
CXCL11, only IFN-g induced their production by LC. In the case of
splenic DC, the production of CXCL10, CXCL9, and CXCL11 was in-
duced by IFN-g, IL-18, LPS, and Poly(I:C). Results are the mean  (SD)
(n¼4). Significant increase (po0.05) compared with the unstimulated
group. Data are representative of four independent experiments.
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7b, c). As for splenic DC, the mode of the regulation of
Th1-type chemokines was identical among CXCL10,
CXCL9, and CXCL11 (Fig 7a–c). Splenic DC produced
CXCL10, CXCL9, and CXCL11 in response to IFN-g, IL-18
(100 ng per mL), LPS, and Poly(I:C). Interestingly, splenic
DC, as a whole, exhibited high ability to produce Th1-type
chemokines in comparison with LC.
Production of Th2-type chemokines and its regulation in
LC and splenic DC As demonstrated above, LC, but not
splenic DC, produced Th2-type chemokines constitutively
during culture even without stimulation. Here, we further
examined the production of CCL22 and CCL17 in response
to various stimuli. The patterns of the regulation of Th2-type
chemokines were rather complicated. As shown in Fig 8a,
CCL22 production by LC was upregulated by tumor ne-
crosis factor-a (TNF-a) (10 ng per mL), granulocyte ma-
crophage colony-stimulating factor (GM-CSF) (1 ng per mL),
IL-1b (10 ng per mL), IL-4 (10 ng per mL), and agonistic anti-
CD40 Ab (20 mg per mL). On the other hand, IFN-g, IL-10
(10 ng per mL), and Poly(I:C) had a significant inhibitory ef-
fect on its production. Other stimuli, such as TGF-b (1 ng per
mL), IL-12, IL-13 (10 ng per mL), IL-18, LPS, and SAC, failed
to affect the production of CCL22 in cultured LC. The mode
of the regulation of CCL17 production in LC was similar to
that of CCL22. Stimulation with TGF-b, TNF-a, IL-4, IL-13,
and anti-CD40 Ab enhanced CCL17 production significant-
ly. In contrast, its production level decreased significantly in
the presence of GM-CSF, IFN-g, IL-10, LPS, SAC, and Poly
(I:C). IL-12 and IL-18 did not cause significant changes in
CCL17 production (Fig 8b). In the case of splenic DC, the
production of CCL22 and CCL17 was found to be regulated
in almost the same way (Fig 8a,b). TNF-a, GM-CSF, IL-1b,
IL-4, IL-12, IL-13, IL-18, and anti-CD40 Ab induced CCL22
and CCL17 production to some extent. When splenic DC
were stimulated with microbial components, such as LPS,
SAC, and Poly(I:C), however, the production of CCL22 and
CCL17 was induced differently. LPS and SAC induced a
high level of CCL22 production, but they did not affect
CCL17 production. Poly(I:C) induced not only CCL22 but
also CCL17 production, although to a much lesser extent.
Another striking finding was that the amounts of Th2-type
chemokines produced by splenic DC were much smaller
than those produced by LC under any conditions tested.
Discussion
In this study, we demonstrated that the chemokine produc-
tion represents an additional diversity between the two dis-
crete populations of mouse DC, epidermal LC, and splenic
DC. LC indeed have the ability to produce functional Th1-
and Th2-type chemokines. With regard to Th1-type che-
mokines, exogenous stimulation was mandatory for their
production both in LC and splenic DC. Only limited stimuli,
such as IFN-g, LPS, and Poly(I:C), induced the production
of Th1-type chemokines, namely, CXCL10, CXCL9, and
CXCL11, both in LC and splenic DC. But the amounts of
CXCL10, CXCL9, and CXCL11, produced by LC in the
presence of such stimuli, were lower than those produced
by splenic DC. Among the Th1-type chemokines, LC pro-
duced CXCL10 in response to IFN-g, IL-12, and microbial
components. Interestingly, only IFN-g, but not microbial
components, was able to induce CXCL9 and CXCL11 pro-
duction in LC. These findings further confirmed our previous
observations that LC exhibited low responsiveness to mi-
crobial components (Fujita et al, 2004b; Mitsui et al, 2004;
Tada et al, 2004). As for Th2-type chemokines, the mode of
the regulation was different from that of Th1-type chemo-
kines. First, even without exogenous stimulation, LC, but
not splenic DC, were able to produce CCL22 and CCL17
constitutively during culture. Although some of the stimuli
induced the production of CCL22 and CCL17 in splenic DC,
Figure 8
Regulation of T helper 2-type chemokines produced by La-
ngerhans cells (LC) and splenic dendritic cells (DC). LC (&) and
splenic DC (’) were purified and cultured (1.5  106 cells per mL per
200 mL in each well) for 48 h with or without various stimuli. The supe-
rnatants were collected and assessed for the concentration of CCL22
(a), CCL17 (b) by ELISA. (a) CCL22 production by LC was upregulated
by tumor necrosis factor-a (TNF-a), granulocyte macrophage colony-
stimulating factor (GM-CSF), interleukin (IL)-1b, IL-4, and anti-CD40
antibody (Ab), and downregulated by interferon-g (IFN-g), IL-10, and
polyinosinic–polycytidylic acid (Poly(I:C)). In splenic DC, its production
was induced by TNF-a, GM-CSF, IL-1b, IL-4, IL-12, IL-13, IL-18, anti-
CD40 Ab, lipopolysaccharide (LPS), Staphylococcus aureus Cowen 1
(SAC), and Poly(I:C). (b) CCL17 production by LC was upregulated
by transforming growth factor-b (TGF-b), TNF-a, IL-1b, IL-4, IL-13,
and anti-CD40 Ab, and downregulated by GM-CSF, IFN-g, IL-10, LPS,
SAC, and Poly(I:C). In splenic DC, its production was induced by TNF-
a, GM-CSF, IL-1b, IL-4, IL-12, IL-13, IL-18, anti-CD40 Ab, and Poly(I:C).
Results are the mean  (SD) (n¼ 4).Significant increase (po0.05)
compared with the unstimulated group. #, Significant decrease
(po0.05) compared with the unstimulated group. Data are represent-
ative of four independent experiments.
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they were produced in much smaller amounts by splenic DC
than by LC under any conditions tested. Other investigators
also reported that mouse splenic DC failed to express
CCL22 and CCL17 at least under some experimental set-
tings in vivo (Tang and Cyster, 1999; Alferink et al, 2003).
Second, the production of Th2-type chemokines was reg-
ulated in a complicated manner. Many factors influenced
the production of CCL22 and CCL17 by LC either positively
or negatively. In particular, IL-4 upregulated and IFN-g
downregulated their production. The regulation of Th2-type
chemokines in LC observed in this study was not simply
because of the changes of cell viability or maturation status.
For example, although GM-CSF increased cell viability and
the expression of co-stimulatory molecules (Salgado et al,
1999a), it downregulated CCL17 production by LC. More-
over, TGF-b decreased cell viability and the expression of
co-stimulatory molecules (Tada et al, 2001; and data not
shown), but it upregulated CCL17 production by LC.
Following cell maturation, LC emigrate from skin to
draining lymph nodes (LN), but some of them are likely to
remain in the skin to interact with T cells there (Katou et al,
2000, 2003). Cytokine availability in the microenvironment of
LC may thus modify the balance of the production of Th1-
and Th2-type chemokines by LC in vivo. But reports on
chemokine expression of LC or skin-derived DC in vivo are
presently limited. Katou et al (2001) reported that DC-de-
rived CCL22 and CCR4 on T cells may be involved in the
formation of in vivo T cell–DC clusters in inflamed skin. Fur-
ther, in vivo observations have so far suggested that LC may
produce CCL22 and CCL17 as they migrate into T cell
zones of LN (Tang and Cyster, 1999; Merad et al, 2000). As
for the inflammatory human skin diseases such as atopic
dermatitis (AD), DC with the mature phenotype are often
found in the dermis of AD patients, and they are shown to
express CCL22 (Vulcano et al, 2001). Moreover, CCL22 is
expressed by dermal DC in AD-like skin lesions of NC/Nga
mice, a model of human AD (Vestergaard et al, 1999). AD is
characterized by enhancement of the expression of Th2
cytokines such as IL-4, as well as suppression of that of
IFN-g in the acute phase (Vestergaard et al, 1999, 2000;
Galli et al, 2000; Kakinuma et al, 2001, 2002a; Wakugawa
et al, 2001). Interestingly, in line with this, our study showed
an enhancing effect of IL-4 on the production of CCL22 and
CCL17, together with an inhibitory effect of IFN-g on the
production of both of them.
In conclusion, this study strengthens the notion that LC
are a unique subset of DC exhibiting some distinct cha-
racteristics. The fact that LC readily produce Th2-type
chemokines in vitro suggests that LC may be an essential
source of these chemokines in the skin in contrast to splenic
DC, which produce them only in small amounts. In addition,
the observation that CLAþ skin homing T cells typically co-
express CCR4 (Campbell et al, 1999) is in accordance with
our finding. Neighboring keratinocytes are also capable of
producing Th1- and Th2-type chemokines. Their produc-
tion, however, is often regulated differently between kera-
tinocytes and LC (Kakinuma et al, 2002b; Xiao et al, 2003b),
further indicating a critical role for LC as the chemokine
producer. Given that LC-derived Th1- and Th2- type
chemokines exhibited functional activity, LC may indeed
contribute to the recruitment of CXCR3- or CCR4-bearing T
cells in vivo. Further investigations are necessary to eluci-
date in vivo relevance of our novel observations in human
skin diseases.
Materials and Methods
Mice BALB/c female mice were purchased from Charles River
Japan (Yokohama, Japan) and maintained until 8–12 weeks of age
under specific pathogen-free conditions in the Animal Facilities of
the University of Tokyo. All animal experiments were approved by
the Animal research Committee of the University of Tokyo.
Reagents and antibodies Mouse rIFN-g, rIL-1b, rIL-4, rIL-10, rIL-
13, rTNF-a, rTGF-b1, rCCL17, rCCL22, and rCXCL9 were pur-
chased from R&D Systems (Minneapolis, Minnesota). rGM-CSF
and rIL-12 were obtained from PeproTech (London, UK). rIL-18 was
purchased from MBL (Nagoya, Japan). SAC (pansorbin) was ob-
tained from Calbiochem (San Diego, California), and LPS (serotype
011: B4) was from Sigma-Aldrich (St Louis, Missouri). Poly(I:C) was
obtained from Amersham Biosciences (Piscatway, New Jersey).
rCXCL10 was provided by DAKO Japan (Kyoto, Japan). Goat
anti-CXCL10 Ab, goat anti-CXCL9 Ab, goat anti-CCL17 Ab, goat
anti-CCL22 Ab, and control goat IgG were obtained from Gen-
zymeTechne (Cambridge, Massachusetts). Rat anti-mouse CD40
monoclonal antibody (mAb) (NA/LE, clone 3/23) was purchased
from BD Biosciences (San Diego, California). Peroxidase-conju-
gated rabbit anti-goat IgG Ab was from MBL.
Puriﬁcation and culture of LC and splenic DC LC were pre-
pared using the previously described panning method, and had a
purity of over 95% (Salgado et al, 1999b; Tada et al, 2000). Briefly,
mouse trunkal skin was separated and treated with dispase (3000
U per mL, Godo Shusei, Tokyo, Japan) in RPMI medium supple-
mented with 10% FCS (RPMI 10 medium) for 3 h at 371C. The
epidermis was separated and incubated in RPMI 10 medium con-
taining 0.025% deoxyribonuclease I (Sigma) for 20 min at room
temperature. An epidermal cell suspension was obtained by
vigorously pipetting the epidermal sheets, and was treated with
mouse anti-mouse I-Ad mAb (1:600; Meiji Seika, Tokyo, Japan) in
RPMI 10 medium for 45 min on ice. The cell suspension in RPMI 10
medium was then incubated in plates coated with goat anti-mouse
IgG (Fc) (1:100; MP Biomedicals, Aurora, Ohio) for 45 min at 41C.
After a wash, adherent cells were collected and designated purified
LC. Splenic DC were purified from spleens of BALB/c mice. A
single cell suspension was obtained by gentle teasing with forceps
and rubbers and filtered through a nylon mesh. Erythrocytes were
lysed by treatment with ammonium chloride. From the remaining
unfractionated cell populations, CD11cþ DC were separated by
positive magnetic selection using microbeads-conjugated hamster
anti-mouse CD11c (Miltenyi Biotec, Belgisch Gladbach, Germany)
and a magnetic cell separator according to the manufacturer’s in-
structions, routinely resulting in 490% purity of CD11cþ DC. LC
and splenic DC were incubated in 96-well culture plates (1.5  106
cells per mL per 200 mL in each well) for up to 48 h, with or without
various cytokines, Ab, or microbial components in a culture me-
dium that consisted of RPMI 10 medium, 100 U per mL of penicillin
G sodium, 100 mg per mL of streptomycin sulfate, and 0.25 mg per
mL of amphotericin B.
Semi-quantitative RT-PCR A semi-quantitative RT-PCR was
used to assess the gene expression of CXCL10, CXCL9, CXCL11,
CCL22, and CCL17 in murine LC and splenic DC. LC and splenic
DC were prepared and cultured for 48 h as described above, and
from the lysate of fresh and cultured LC and splenic DC, mRNA
was isolated using the Quickprep Micro mRNA Purification Kit
(Pharmacia Biotech, Uppsala, Sweden). Complementary DNA was
synthesized by RT using random hexamers and mouse reverse
transcriptase (First-Strand cDNA Synthesis Kit; Pharmacia Bio-
tech). The PCR was performed in a programmable thermal cycler
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(Perkin-Elmer Co., Norwalk, Connecticut). The primers used for
amplification of CXCL10 (Kuroda et al, 2001), CXCL9 (Park et al,
2001), CXCL11 (Lacroix-Lamande et al, 2002), CCL22 (Kuroda
et al, 2001), CCL17 (Xiao et al, 2003a), and glyceraldehyde-3-
phosphate dehydrogenase (Xiao et al, 2003a) were described
elsewhere. All reactions were run at 941C per 1 min, 561C per
1 min, 721C per 2 min for 35 cycles. The PCR was within the linear
range. The PCR products were analyzed on 2.5% agarose gels and
visualized by ethidium bromide staining and UV illumination.
Measurement of CXCL10 and CCL22 Culture supernatants were
collected, stored at 201C, and subjected to the quantification of
protein levels of CXCL10 and CCL22 by competitive ELISA inhi-
bition assay as previously described (Kuroda et al, 2001). Briefly,
ELISA plates were coated with 100 mL of rCXCL10 or rCCL22 at
250 ng per mL in phosphate-buffered saline (PBS) containing 0.1%
BSA at 41C for 18 h. Then the wells were washed and blocked with
300 mL of RPMI 10 medium at 371C for 30 min. Standard solutions
(40,000–625 pg per mL in RPMI 10 medium) or culture supernat-
ants and equal volumes of 100 ng per mL of anti-CXCL10 Ab
or 400 ng per mL of anti-CCL22 Ab were mixed in microtubes
and incubated at 371C for 1 h. After the incubation, 200 mL of
prepared standard or sample solution was transferred to each
well of CXCL10- or CCL22-coated plates, and the plates were
kept at 41C for 18 h. The wells were washed and 100 mL of per-
oxidase-conjugated rabbit anti-goat IgG Ab (diluted 1:2000 in
PBS containing 0.05% Tween 20 and 1% BSA) was added. The
plates were incubated at 371C for 2 h. Then they were washed and
100 mL of substrate (0.04% o-phenylenediamine, 0.01% H2O2 in 50
mM disodium hydrogen phosphate, and 150 mM citric acid, pH 5)
was added to the wells. The plates were incubated at room tem-
perature for 30 min. The enzyme reaction was stopped by the
addition of 25 mL of 8 N H2SO4, and the absorbance at 490 nm was
measured.
Measurement of CXCL9, CXCL11, and CCL17 Culture supe-
rnatants were collected, stored at 201C, and subjected to the
quantification of protein levels of CXCL9, CXCL11, and CCL17 by
ELISA using commercially available mouse CXCL9, CXCL11, and
CCL17 immunoassay kits (R&D Systems), respectively, according
to the manufacturer’s instructions. Each sample was tested in
duplicate.
Chemotaxis assay Chemotaxis assay was carried out using
mouse CCR4- or CXCR3-transfected 2B4 T cells (Gao et al,
2003). Chemotaxis of the transfectants was assessed in 24-well
transwells equipped with 5 mM pore polycarbonate membranes
(Transwell, Corning Costar Corp., Cambridge, Masschusetts). Cells
(1  106) suspended in 100 mL of RPMI 10 medium were transferred
to the upper chamber. For the chemotaxis of CCR4 transfectant, the
supernatants of 48 h cultured unstimulated LC and splenic DC were
used. Culture supernatants and RPMI 10 medium with or without
recombinant chemokine were preincubated with or without 2 mg per
mL of anti-CCL17 mAb, or 10 mg per mL of anti-CCL22 mAb, or both
for 30 min at room temperature. They were then transferred to the
lower chamber in 600 mL for each group. After an incubation period
of 3 h at 371C, the upper chambers were removed, and the cells in
the lower chamber of each well were collected and counted using
a Coulter Counter (Beckman Coulter, Jersey City, New Jersey).
Chemotaxis of CXCR3 transfectant was carried out in the same way
using the supernatants of 48 h IFN-g-stimulated LC and splenic DC.
In this case, to neutralize the activity of chemokines, 4 mg per mL of
anti-CXCL10 mAb and 2 mg per mL of anti-CXCL9 mAb were used.
All assays were carried out in triplicate.
Statistical analysis Student’s t-test was used to analyze the re-
sults, and a p-value of less than 0.05 was considered statistically
significant.
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